Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06361433
Other study ID # R5-11
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date December 1, 2023
Est. completion date February 2026

Study information

Verified date April 2024
Source Hokkaido University Hospital
Contact Masahito Kawabori, MD, PHD
Phone +81117065987
Email masahitokawabori@yahoo.co.jp
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to test intracerebral transplantation of stem cell product in patient with chronic intracerebral hemorrhage. The main questions aims to answer are: - The safety of the product - The efficacy of the product


Description:

Introduction: Intracerebral hemorrhage stands as a leading global cause of death and disability, posing a significant challenge with limited treatment options, especially for chronic patients. Recent advances of stem cell therapies have opened new avenues for therapeutic potential. The investigators' previous preclinical research has demonstrated that intracerebral transplantation of bone marrow stromal cells (BMSCs) combined with a recombinant human collagen type I scaffold enables higher cell survival and engraftment, holds promising potential. The investigators present the protocol for a novel clinical trial, named "Research on Advanced Intervention using Novel Bone Marrow Stem Cells for Chronic Intracerebral Hemorrhage" (RAINBOW-Hx). Methods and Analysis: RAINBOW-Hx is a phase I/II, open-label, uncontrolled study with the primary objective of assessing the safety and efficacy of intracerebral transplantation of autologous BMSCs combined with the scaffold (HUFF-01) in patients with chronic intracerebral hemorrhage. Eight patients, experiencing moderate to severe neurological deficits for 12 months or longer, will be enrolled. The hemorrhage location will be limited to the basal ganglia and thalamus. Approximately 50 mL of bone marrow will be extracted from the iliac bone of each patient, and BMSCs will be cultured using autologous platelet lysate. Three days before transplantation, BMSCs will be combined with the scaffold to generate HUFF-01. Each patient will receive a 50,000 HUFF-01 dose, containing approximately 50 million BMSCs, through stereotactic transplantation into the hemorrhagic cavity. Neurological assessments, magnetic resonance imaging, 18F-fluorodeoxyglucose positron emission tomography, and 123I-Iomazenil single-photon emission computed tomography will be performed for one year after administration.


Recruitment information / eligibility

Status Recruiting
Enrollment 8
Est. completion date February 2026
Est. primary completion date February 2026
Accepts healthy volunteers No
Gender All
Age group 20 Years to 70 Years
Eligibility Inclusion Criteria: - 1. Age between 20 and 70 years - 2. Clinical diagnosis of intracerebral hemorrhage 12 month or more from onset - 3. Hemorrhagic location of unilateral basal ganglia or thalamus - 4. Moderate to severe neurological symptoms; mRS 3 or 4, and Brunnstrom stage ? or IV - 5. No significant neurological impairment before hemorrhage (Pre-hemorrhagic mRS of 0 or 1) - 6. Subjects who can give informed consent by its self Exclusion Criteria: - 1. Severe microbleeds found by T2* - 2. Hemorrhagic cavity less than 2 mL - 3. The hemorrhage is due to arteriovenous malformation, cerebral aneurysm, and Moyamoya disease - 4. Subject showing obvious communication between the hemorrhagic cavity and lateral ventricle on MRI - 5. Subject showing severe lower extremity contracture (Maximum knee extension less than -15 degrees, Maximum ankle flexion less than 0 degree) - 6. Subject's body weight less than 45 kg for male and 40kg for female - 7. Anaemia (Hg < 10·0 g/dL) - 8. Thrombocytopaenia (platelet count < 100,000/mm3) - 9. Severe heart disease (ischaemic heart disease, heart failure) - 10. Uncontrolled hypertension, despite antihypertensive therapy - 11. Carriers of infectious disease: syphilis, HBV, HCV, HIV-1/HIV-2, HTLV-1, parvovirus B19 - 12. Pregnant or lactating or expecting to become pregnant during the study - 13. History of malignancy - 14. Systemic organ failure ALT = 3·0× upper limit of normal Total bilirubin = 1·5× upper limit of normal Serum creatinine = 1·5× upper limit of normal - 15. Known serious allergy to any agents used in the study - 16. Contraindication for magnetic resonance imaging - 17. Any condition that in the judgement of the investigator would place the patient at undue risk

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
HUFF-01
autologous MSC combined with scaffold

Locations

Country Name City State
Japan Hokkaido University Hospital Sapporo Hokkaido

Sponsors (2)

Lead Sponsor Collaborator
Hokkaido University Hospital Japan Agency for Medical Research and Development

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 Listing unexpected CTCAE grade changes in physiological (physical examination/blood test) and Radiographical (MRI/CT) examination one year
Secondary Change in mRS examination Percentage of the patients number who showed improvement of mRS (0-6, higher score means worse outcome) of more than 1 point One year
Secondary Change in NIHSS examination Mean improvement of NIHSS (0-42, higher score means worse outcome) One year
Secondary Change in FIM examination Mean improvement of FIM (18-126, higher score means better outcome) One year
Secondary Change in Fugl-Myer examination Mean improvement of Fugl-Myer (0-226, higher score means better outcome) One year
Secondary Change in Barthal index examination Mean improvement of Barthal index (0-100, higher score means better outcome) One year
Secondary Change in FDG-PET examination Mean improvement of FDG-PET set for ipsilateral motor cortex One year
Secondary Change in IMZ-SPECT examination Mean improvement of IMZ-SPECT set for ipsilateral motor cortex One year
See also
  Status Clinical Trial Phase
Recruiting NCT05089331 - ROSE-Longitudinal Assessment With Neuroimaging
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Active, not recruiting NCT04522102 - Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral haemorrhaGe (ASPIRING)-Pilot Phase Phase 3
Terminated NCT04178746 - PRONTO: Artemis in the Removal of Intraventricular Hemorrhage in the Hyper-Acute Phase
Not yet recruiting NCT03956485 - Multicentre Registry of Patients With Spontaneous Acute Intracerebral Hemorrhage in Catalonia (HIC-CAT).
Enrolling by invitation NCT02920645 - Multicenter Validation of the AVICH Score N/A
Recruiting NCT02625948 - Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign Phase 2
Completed NCT02478177 - Addressing Real-world Anticoagulant Management Issues in Stroke
Completed NCT01971359 - Clinical Outcomes Following Parafascicular Surgical Evacuation of Intracerebral Hemorrhage: A Pilot Study N/A
Completed NCT01261091 - Early Tracheostomy in Ventilated Stroke Patients N/A
Terminated NCT00990509 - Albumin for Intracerebral Hemorrhage Intervention Phase 2
Completed NCT00716079 - The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial N/A
Recruiting NCT00222625 - rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets Phase 2
Recruiting NCT05095857 - The Anesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury Phase 4
Recruiting NCT04548596 - NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
Not yet recruiting NCT06429332 - International Care Bundle Evaluation in Cerebral Hemorrhage Research Phase 4
Recruiting NCT05492474 - Cranial Ultrasound for Prehospital ICH Diagnosis N/A
Not yet recruiting NCT05502874 - Multicenter Registry for Assessment of Markers of Early Neurological Deterioration in Primary Intracerebral Hemorrhage
Recruiting NCT04604587 - MRI-visible Enlarged Perivascular Spaces and the Alteration of Lymphatic Drainage System in CAA Phase 3
Recruiting NCT05504941 - Detection of an Endovascular Treatment Target in Patients With an Acute, Spontaneous Intracerebral Hemorrhage N/A